Latest Insider Transactions at Enanta Pharmaceuticals Inc (ENTA)
This section provides a real-time view of insider transactions for Enanta Pharmaceuticals Inc (ENTA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ENANTA PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ENANTA PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2021
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Open market or private sale
|
Direct |
6,000
-8.85%
|
$270,000
$45.58 P/Share
|
|
Dec 15
2020
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,201
-0.32%
|
$92,442
$42.52 P/Share
|
|
Dec 15
2020
|
Jay R. Luly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+1.09%
|
-
|
|
Dec 15
2020
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,540
-0.48%
|
$64,680
$42.52 P/Share
|
|
Dec 15
2020
|
Yat Sun Or Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,250
+1.62%
|
-
|
|
Dec 15
2020
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,540
-5.41%
|
$64,680
$42.52 P/Share
|
|
Dec 15
2020
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,250
+15.56%
|
-
|
|
Dec 15
2020
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
770
-1.36%
|
$32,340
$42.52 P/Share
|
|
Dec 15
2020
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,625
+4.44%
|
-
|
|
Dec 15
2020
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,540
-3.52%
|
$64,680
$42.52 P/Share
|
|
Dec 15
2020
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,250
+10.71%
|
-
|
|
Dec 03
2020
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,667
+4.15%
|
$50,010
$30.0 P/Share
|
|
Nov 20
2020
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
26,500
+3.77%
|
-
|
|
Nov 20
2020
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+12.36%
|
-
|
|
Nov 20
2020
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+2.37%
|
-
|
|
Nov 20
2020
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+24.65%
|
-
|
|
Nov 20
2020
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+17.09%
|
-
|
|
Nov 11
2020
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,480
+6.99%
|
$6,960
$2.54 P/Share
|